BOSTON--(BUSINESS WIRE)--Click to Tweet this News
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for cramps and spasms associated with severe neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) and peripheral neuropathies such as Charcot-Marie-Tooth (CMT), today reported financial results for the quarter ended March 31, 2017 and provided an update on its clinical development and corporate activities.
“Now that our IND is active for our ALS study, we are poised to expand our clinical program and will submit a protocol to the FDA to start a clinical trial of FLX-787 to treat patients with CMT neuropathy. With two Phase 2 clinical trials in ALS and CMT expected to initiate this summer in the US, together with our exploratory Phase 2 studies already underway in Australia, FLX-787 will be amongst the most advanced, novel compounds in the clinic for ALS and CMT,” stated Christoph Westphal, M.D., Ph.D., Chair and CEO of Flex Pharma. “Our efforts are focused on creating value by accelerating the development of FLX-787 to address the significant unmet medical need of patients suffering from debilitating cramps and spasms as a consequence of severe neurological diseases.”
